72 MUONNET H J[removed]

First Page		Document Content
Date: 2014-04-25 15:36:35 Rare diseases Fibrodysplasia ossificans progressiva Harry Raymond Eastlack ACVR1 Ossification Bone morphogenetic protein 4 Bone disease Osteoporosis Health Biology International FOP Association		72 MUONNET H J[removed] Add to Reading List Source URL: newsroom.aaos.org Download Document from Source Website File Size: 684,68 KB Share Document on Facebook

	Clementia Pharmaceuticals Announces Open-Label Phase 2 Extension Study of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva DocID: 1f9bL - View Document
	Clementia Pharmaceuticals Highlights Role of Patient Community in the Fight Against Fibrodysplasia Ossificans Progressiva (FOP) Company to Host Webcast to Pay Tribute to FOP Community and Recognize Rare Disease Day MONTR DocID: 1eVqM - View Document
	Fibrodysplasia Ossificans Progressiva Facts in Brief WWW.IFOPA.ORG What is Fibrodysplasia Ossificans Progressiva (FOP)? A musculoskeletal condition where, after birth DocID: 1d3oF - View Document
	Jeannie Peeper International Fibrodysplasia Ossificans Progressiva Association, Inc. President and Founder I was born August 30, 1958 in Ypsilanti, Michigan, one of five children. At birth, my parents realized my toes we DocID: 1cVhz - View Document
	CLEMENTIA PHARMACEUTICALS MARKS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) AWARENESS DAY MONTREAL, CANADA, April 23, Clementia Pharmaceuticals, Inc., a privately held clinical stage biotechnology company dedicat DocID: 1cixd - View Document